Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (2)	4/6/2000 9:14:00 PM
From: Mike McFarland	Respond to of 368

ZFPs and Their Role in Angiogenesis It is widely accepted that disease processes could be controlled by the selective regulation of specific disease-related genes. The ZFP platform, with its ability to generate highly specific engineered transcription factors for the regulation of selected genes, is capable of rapidly and rationally producing proprietary pharmaceutical candidates for the therapeutic regulation of specific genes in a broad spectrum of clinical indications. Because they function at the DNA level, ZFPs can be precisely engineered to recognize a specific and unique DNA sequence within an entire genome. Such versatility in design and specificity in targeting means that ZFPs can be generated to discriminate between closely related genes. In addition, ZFPs can work through either activation or repression of disease-related genes. Sangamo has active research and development programs in the application of ZFPs to cardiovascular disease, cancer, and infectious diseases. noonanrusso.com

To: Mike McFarland who wrote (2)	4/6/2000 9:27:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 368

The Model T (these are two big names to follow)....... Science 1997 Jan 31;275(5300):657-61 A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Greisman HA, Pabo CO Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. A method is described for selecting DNA-binding proteins that recognize desired sequences. The protocol involves gradually extending a new zinc finger protein across the desired 9- or 10-base pair target site, adding and optimizing one finger at a time. This procedure was tested with a TATA box, a p53 binding site, and a nuclear receptor element, and proteins were obtained that bind with nanomolar dissociation constants and discriminate effectively (greater than 20,000-fold) against nonspecific DNA. This strategy may provide important information about protein-DNA recognition as well as powerful tools for biomedical research.